Rigel Pharmaceuticals inks worldwide agreement to develop and commercialize VEPPANU

Rigel Pharmaceuticals inks worldwide agreement to develop and commercialize VEPPANU
Rigel secures VEPPANU license deal

Rigel Pharmaceuticals has announced an exclusive global license agreement to develop, manufacture, and commercialize VEPPANU (vepdegestrant).

The move positions Rigel Pharmaceuticals to further expand its presence in the oncology sector. VEPPANU, also known as vepdegestrant, is poised to become a key product in the company’s pipeline. Additional details and the webcast replay are available via the company's provided links.

Rigel previously signed a global license deal to develop, manufacture and commercialize VEPPANU (vepdegestrant). The company is scheduled to release its Q1 2026 financial results and provide a business update on May 5. These developments come as Rigel pursues a stronger position in oncology research and development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.